Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 30;385(27):2585-2586.
doi: 10.1056/NEJMc2110300. Epub 2021 Dec 15.

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

Hiam Chemaitelly  1 , Roberto Bertollini  2 , Laith J Abu-Raddad  3 ; National Study Group for COVID-19 Epidemiology
Collaborators, Affiliations

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

Hiam Chemaitelly et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cumulative Incidence of Documented SARS-CoV-2 Reinfection with the Beta or Alpha Variant.
Kaplan–Meier curves show the cumulative incidence of documented reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) beta (B.1.351) or alpha (B.1.1.7) variant in the cohort of persons with previous SARS-CoV-2 infection as confirmed on polymerase-chain-reaction assay (previous-infection cohort), as compared with the incidence of documented SARS-CoV-2 infection in the matched cohort of antibody-negative persons (antibody-negative cohort). Persons in the cohorts were matched in a 1:1 ratio on the basis of age, sex, and nationality. Follow-up was from March 8 to April 21, 2021.
See this image and copyright information in PMC

References

    1. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 2021;27:917-924. - PubMed
    1. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187-189. - PMC - PubMed
    1. Abu-Raddad LJ, Chemaitelly H, Malek JA, et al. Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting. Clin Infect Dis 2021;73(7):e1830-e1840. - PMC - PubMed
    1. Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine 2021;35:100861-100861. - PMC - PubMed
    1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and its reinfections in Qatar: a nationally-representative cohort study. PLoS Med. in press. - PMC - PubMed

Publication types

Substances

Supplementary concepts